{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-25-000069","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2025-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.744803+00:00","generated_at":"2026-05-18T02:25:10.519004+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Krystal Biotech subsidiary Jeune reports 100% investigator-rated GAIS improvement in Phase 1 KB304 study","bullets":["PEARL-2 Phase 1 trial: 100% of KB304-treated subjects achieved ≥1-point investigator GAIS improvement at 1,2,3 months vs 14-29% for placebo.","81.8% of KB304 subjects reported improved satisfaction on SSQ at 3 months vs 14.3% for placebo; improvements also seen in elasticity, crepiness, hydration, radiance.","Safety consistent with prior KB301 experience: no severe or drug-related serious AEs; AEs mild-to-moderate and decreased with subsequent doses.","Company plans to meet with FDA in H2 2025 to align on Phase 2 protocol; target Phase 2 start in H1 2026 for décolleté wrinkles.","KB304 is first candidate to combine collagen (COL3) and elastin delivery via gene therapy to restore skin naturally."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-25-000069","json":"https://secwatch.observer/filing/0001711279-25-000069.json","markdown":"https://secwatch.observer/filing/0001711279-25-000069.md","text":"https://secwatch.observer/filing/0001711279-25-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000069/0001711279-25-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000069/krys-20250724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T02:25:10.519004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}